Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Fig. 2

SRI4 response at week 52 of treatment. In patients with SELENA-SLEDAI ≥ 4 at baseline; †covariates include the treatment group, study, baseline SELENA-SLEDAI score (≤ 9 versus ≥ 10), baseline proteinuria level (< 2 g/24 h versus ≥ 2 g/24 h equivalent) and race (African descent or Native American descent versus other). For the overall analysis, the BLyS mRNA/IFN-1/BLyS protein subgroup was included as an additional covariate. BLyS B lymphocyte stimulator, CI confidence interval, IFN interferon, IFN-1 type 1 IFN-inducible gene signature, mRNA messenger ribonucleic acid, SELENA-SLEDAI Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index, SRI Systemic Lupus Erythematosus Responder Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us